MedCity News
Wilson Sonsini tops Life Sciences Law Stiff Index for 2nd straight year
Cellular therapy just got real: Novartis is the very first to get FDA approval for CAR-T treatment (Updated)
At $475,000, the therapy isn’t cheap but for its part, Novartis has said patients would only pay the total whack if they react to the therapy by the end of the very first month.
Gilead maps out cellular therapy strategy with Kite acquisition
Gilead has been looking for ways to add to its portfolio beyond infectious-disease treatments especially in light of the company’s declining hepatitis C drugs sales, The Wall Street Journal observed.
Spin the script
Check out the key building blocks for switching ROI to IOR and measure the influence of relationships with patients…
It’s not a competition but… Kite’s CAR-T therapy just claimed a very first in Europe
Santa Monica, California-based Kite Pharma has hopped the Atlantic to file the very first Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for a CAR-T therapy.
A home run for CAR-Ts: Novartis wins unanimous support from pro panel
A 10-person panel of experts has unanimously recommended FDA approve a pioneering CAR-T therapy from Novartis, CTL019, for patients with relapsed and refractory B-cell acute lymphoblastic leukemia (ALL).
Why the immune system is our best bet to battle cancer
Immuno-oncology is on a roll, yet many questions remain unanswered. What incites an immune response and where does the future of the field lie?
GE Ventures spin-out Vineti raises $13.75M for sophisticated biomanufacturing
For all the complexity of CAR-T autologous transplant technology, GE Ventures spin-out Vineti has a plain question to ask: What if the wrong cells are infused back into the patient?
Bluebird is pretty chirpy about its anti-BCMA CAR-T therapy results
You know you’re on to something worthwhile when your explore leader can’t fairly hold back the tears when introduced with the final data. On Monday, Bluebird Bio will share that same data at ASCO 2017.
Very first come, very first served: Novartis finalizes CAR-T application, claims priority review
Novartis announced Wednesday that the FDA has accepted a finalized biologics license application for its lead CAR-T candidate, CTL019, topping it off with a priority review to expedite the process.
Jet-setting CAR-Ts: Kite details commercialization plans at #JPM17
One of the thickest biotech whirr fields in latest years, CAR-T immunotherapy is on the cusp of gaining an FDA approval. There is no precedent for what comes next. On Wednesday, we got an early peek as Kite Pharma outlined its commercialization plan in a packed presentation at #JPM17.
Interoperability across organizational boundaries improves patient care and quality
Eagle Physicians & Associates is a multispecialty health care practice suggesting excellence in patient care through eight…
Bluebird bio announces positive CAR-T results
It’s not all doom and gloom for CAR-T immunotherapy. One week after the death of two patients in a trial by Juno Therapeutics, early-stage competitor bluebird bio has released positive interim results for its Phase one trial.
Novartis closing cell therapy unit, but won’t abandon CAR-T work
Novartis will proceed its T-cell research at the University of Pennsylvania. The Novartis-Penn Center for Advanced Cellular Therapeutics opened in Philadelphia this year.
Standing on the shoulders of stem cell gene therapists
With a switch from T cells to stem cells and a roller-coaster hype rail, the gene therapy field has delivered on its promise from over twenty five years ago with a medicine that now offers a real hope for children with ADA-SCID.
Will CAR-T supply on the promise of widespread therapeutic improvement?
So where are we with CAR-T? Is it the innovative, transformative, disruptive, paradigm-changing cancer therapy we all hope for, or is it another incremental improvement?
Precision BioSciences’ $1.6B Baxalta deal could make CAR-T allogeneic
Making CAR-T therapeutics allogeneic would significantly improve its scalability – but it’s been a harsh objective to conceive. Precision BioSciences’ genome editing deal with Baxalta could make it a reality.
Aurora Biopharma tackling glioblastoma with CAR-T immunotherapy; plans to raise $20M
Immunotherapy is emerging as a powerful device to treat glioblastoma – an aggressive form of brain cancer. Cambridge startup is developing a CAR-T treatment to the disease, and is raising a $20 million Series A to do so.
CAR-T Archives – MedCity News
MedCity News
Wilson Sonsini tops Life Sciences Law Hard Index for 2nd straight year
Cellular therapy just got real: Novartis is the very first to get FDA approval for CAR-T treatment (Updated)
At $475,000, the therapy isn’t cheap but for its part, Novartis has said patients would only pay the utter whack if they react to the therapy by the end of the very first month.
Gilead maps out cellular therapy strategy with Kite acquisition
Gilead has been looking for ways to add to its portfolio beyond infectious-disease treatments especially in light of the company’s declining hepatitis C drugs sales, The Wall Street Journal observed.
Roll the script
Check out the key building blocks for switching ROI to IOR and measure the influence of relationships with patients…
It’s not a competition but… Kite’s CAR-T therapy just claimed a very first in Europe
Santa Monica, California-based Kite Pharma has leaped the Atlantic to file the very first Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for a CAR-T therapy.
A home run for CAR-Ts: Novartis wins unanimous support from experienced panel
A 10-person panel of experts has unanimously recommended FDA approve a pioneering CAR-T therapy from Novartis, CTL019, for patients with relapsed and refractory B-cell acute lymphoblastic leukemia (ALL).
Why the immune system is our best bet to battle cancer
Immuno-oncology is on a roll, yet many questions remain unanswered. What incites an immune response and where does the future of the field lie?
GE Ventures spin-out Vineti raises $13.75M for elaborate biomanufacturing
For all the complexity of CAR-T autologous transplant technology, GE Ventures spin-out Vineti has a plain question to ask: What if the wrong cells are infused back into the patient?
Bluebird is pretty chirpy about its anti-BCMA CAR-T therapy results
You know you’re on to something worthwhile when your probe leader can’t fairly hold back the tears when introduced with the final data. On Monday, Bluebird Bio will share that same data at ASCO 2017.
Very first come, very first served: Novartis finalizes CAR-T application, claims priority review
Novartis announced Wednesday that the FDA has accepted a finalized biologics license application for its lead CAR-T candidate, CTL019, topping it off with a priority review to expedite the process.
Jet-setting CAR-Ts: Kite details commercialization plans at #JPM17
One of the largest biotech whirr fields in latest years, CAR-T immunotherapy is on the cusp of gaining an FDA approval. There is no precedent for what comes next. On Wednesday, we got an early peek as Kite Pharma outlined its commercialization plan in a packed presentation at #JPM17.
Interoperability across organizational boundaries improves patient care and quality
Eagle Physicians & Associates is a multispecialty health care practice suggesting excellence in patient care through eight…
Bluebird bio announces positive CAR-T results
It’s not all doom and gloom for CAR-T immunotherapy. One week after the death of two patients in a trial by Juno Therapeutics, early-stage competitor bluebird bio has released positive interim results for its Phase one trial.
Novartis closing cell therapy unit, but won’t abandon CAR-T work
Novartis will proceed its T-cell research at the University of Pennsylvania. The Novartis-Penn Center for Advanced Cellular Therapeutics opened in Philadelphia this year.
Standing on the shoulders of stem cell gene therapists
With a switch from T cells to stem cells and a roller-coaster hype rail, the gene therapy field has delivered on its promise from over twenty five years ago with a medicine that now offers a real hope for children with ADA-SCID.
Will CAR-T produce on the promise of widespread therapeutic improvement?
So where are we with CAR-T? Is it the innovative, transformative, disruptive, paradigm-changing cancer therapy we all hope for, or is it another incremental improvement?
Precision BioSciences’ $1.6B Baxalta deal could make CAR-T allogeneic
Making CAR-T therapeutics allogeneic would significantly improve its scalability – but it’s been a raunchy aim to conceive. Precision BioSciences’ genome editing deal with Baxalta could make it a reality.
Aurora Biopharma tackling glioblastoma with CAR-T immunotherapy; plans to raise $20M
Immunotherapy is emerging as a powerful device to treat glioblastoma – an aggressive form of brain cancer. Cambridge startup is developing a CAR-T treatment to the disease, and is raising a $20 million Series A to do so.
CAR-T Archives – MedCity News
MedCity News
Wilson Sonsini tops Life Sciences Law Stiff Index for 2nd straight year
Cellular therapy just got real: Novartis is the very first to get FDA approval for CAR-T treatment (Updated)
At $475,000, the therapy isn’t cheap but for its part, Novartis has said patients would only pay the utter whack if they react to the therapy by the end of the very first month.
Gilead maps out cellular therapy strategy with Kite acquisition
Gilead has been looking for ways to add to its portfolio beyond infectious-disease treatments especially in light of the company’s declining hepatitis C drugs sales, The Wall Street Journal observed.
Spin the script
Check out the key building blocks for switching ROI to IOR and measure the influence of relationships with patients…
It’s not a competition but… Kite’s CAR-T therapy just claimed a very first in Europe
Santa Monica, California-based Kite Pharma has hopped the Atlantic to file the very first Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for a CAR-T therapy.
A home run for CAR-Ts: Novartis wins unanimous support from experienced panel
A 10-person panel of experts has unanimously recommended FDA approve a pioneering CAR-T therapy from Novartis, CTL019, for patients with relapsed and refractory B-cell acute lymphoblastic leukemia (ALL).
Why the immune system is our best bet to battle cancer
Immuno-oncology is on a roll, yet many questions remain unanswered. What incites an immune response and where does the future of the field lie?
GE Ventures spin-out Vineti raises $13.75M for sophisticated biomanufacturing
For all the complexity of CAR-T autologous transplant technology, GE Ventures spin-out Vineti has a elementary question to ask: What if the wrong cells are infused back into the patient?
Bluebird is pretty chirpy about its anti-BCMA CAR-T therapy results
You know you’re on to something worthwhile when your probe leader can’t fairly hold back the tears when introduced with the final data. On Monday, Bluebird Bio will share that same data at ASCO 2017.
Very first come, very first served: Novartis finalizes CAR-T application, claims priority review
Novartis announced Wednesday that the FDA has accepted a finalized biologics license application for its lead CAR-T candidate, CTL019, topping it off with a priority review to expedite the process.
Jet-setting CAR-Ts: Kite details commercialization plans at #JPM17
One of the thickest biotech whirr fields in latest years, CAR-T immunotherapy is on the cusp of gaining an FDA approval. There is no precedent for what comes next. On Wednesday, we got an early peek as Kite Pharma outlined its commercialization plan in a packed presentation at #JPM17.
Interoperability across organizational boundaries improves patient care and quality
Eagle Physicians & Associates is a multispecialty health care practice suggesting excellence in patient care through eight…
Bluebird bio announces positive CAR-T results
It’s not all doom and gloom for CAR-T immunotherapy. One week after the death of two patients in a trial by Juno Therapeutics, early-stage competitor bluebird bio has released positive interim results for its Phase one trial.
Novartis closing cell therapy unit, but won’t abandon CAR-T work
Novartis will proceed its T-cell research at the University of Pennsylvania. The Novartis-Penn Center for Advanced Cellular Therapeutics opened in Philadelphia this year.
Standing on the shoulders of stem cell gene therapists
With a switch from T cells to stem cells and a roller-coaster hype rail, the gene therapy field has delivered on its promise from over twenty five years ago with a medicine that now offers a real hope for children with ADA-SCID.
Will CAR-T produce on the promise of widespread therapeutic improvement?
So where are we with CAR-T? Is it the innovative, transformative, disruptive, paradigm-changing cancer therapy we all hope for, or is it another incremental improvement?
Precision BioSciences’ $1.6B Baxalta deal could make CAR-T allogeneic
Making CAR-T therapeutics allogeneic would significantly improve its scalability – but it’s been a rough purpose to conceive. Precision BioSciences’ genome editing deal with Baxalta could make it a reality.
Aurora Biopharma tackling glioblastoma with CAR-T immunotherapy; plans to raise $20M
Immunotherapy is emerging as a powerful implement to treat glioblastoma – an aggressive form of brain cancer. Cambridge startup is developing a CAR-T treatment to the disease, and is raising a $20 million Series A to do so.
No comments